Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

Running, not enrolling

Conditions studied: Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19

In brief

The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function.

Key facts

Study ID

NCT05040659

Run by

Massachusetts General Hospital

People needed

1000

Starts

2022-11-14

Expected to finish

2027-12-31

Last updated by the study team

2026-03-06

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Known anosmia (for anosmic patients only)
• Age greater than or equal to 18
• Access to phone, tablet or computer connected to the internet.

You may not qualify if…

• Known odor-evoked adverse effects, e.g. asthma.
• For asymptomatic participants:
• Inclusion criteria
• No symptoms of COVID infection at the time of enrollment.
• Age greater than or equal to 18
• Access to phone, tablet or computer connected to the internet.
• Exclusion criteria
• Known odor-evoked adverse effects, e.g. asthma.
• For participants with COVID-19-related smell loss:
• Inclusion criteria
• Past infection of SARS-CoV-2 virus as validated by a previous PCR or antigen test
• Age greater than or equal to 18
• Access to phone, tablet or computer connected to the internet.
• Exclusion criteria
• Known odor-evoked adverse effects, e.g. asthma.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.